HI version is available. Content is displayed in original English for accuracy.
Advertisement
Advertisement
⚡ Community Insights
Discussion Sentiment
75% Positive
Analyzed from 664 words in the discussion.
Trending Topics
#drug#things#helps#need#face#something#hair#loss#oral#formulation

Discussion (29 Comments)Read Original on HackerNews
For example, it helps me install academic software, debug things. It helps me take a large dataset and write scripts to ask questions. It helps me go through experiment drafts to see if I'm missing things. It helps me remember obscure formulas I use every 6 months. It has not, at least in my experience, come up with anything truly novel.
A concrete example: AlphaFold is great...to come up with a starting model for a chimeric fusion or something. What would have taken me 1-2 hours fumbling around in PDB or CIF files is now a quick prompt.
I think that was originally linked but got changed to the £30 to Elsevier version for some reason.
Wheres my follicles dammit?
its slow-release oral minoxidil formulation called MINX. AI helped with the formulation [1].
its in in similar category as VDPHL01. Hundreds of millions if not a billion dollars has been invested into Veradermics, and their main product is VDPHL01 (also an extended-release oral formulation).
[1] https://x.com/anagenxyz/status/2071601868841595082
Only for values of 'all' that exclude well-connected members of the billionaire class and their select associates.
The lack of comparable data and testability really does seem to be a challenge. I wonder if people would be more willing to collect and share lots of health data if the collecting company was a non-profit dedicated to anonymizing it.
Ketamin should have huge impacts on neuro/brain plasticity when used properly (i.e. in therapy)
In therapy as well.
Please. Please let some people with power and influence understand this lesson sooner rather than later. I understand the reasons that's unlikely to occur, but usually the impact isn't quite so drastic and expensive as this is. Just because something is new and shiny doesn't mean that it'll produce the outcomes you need at the other end, and until it's shown that capability your approach to it should be MODERATE.
It's also worth mentioning that drug development timelines typically exceed the interval in which these technologies have been available (or at least effective). Measuring impact will take a long time.
No? Well fancy that! :)